ASP Isotopes

ASPI · NASDAQ

$2.03−$0.025 (−1.22%)TodayMarket closed · Oct 20, 7:46 PM ET

Prev close $2.05

ASPI analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $13.26 (+553.2% upside)

Low: $11.11
Now: $2.03
High: $15.75

Upgrades and downgrades

The latest rating actions, newest first

ASPI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Canaccord Genuity	Apr 14, 2026	Maintains	Buy	$11.00	34%
Cantor Fitzgerald	Dec 4, 2025	Initiates	Overweight	$13.00	29%
Canaccord Genuity	Nov 24, 2025	Maintains	Buy	$11.00	34%

The case for and against

Updated May 26, 2026

Bull case

ASP Isotopes is positioning itself for significant revenue growth by 2026 through expansions in nuclear medicine, quantum technology, and diversified geographical operations. Furthermore, their partnership with the South African Nuclear Energy and funding from the U.S. DOE demonstrate strong support for their unique and valuable position as the sole commercial provider of highly-enriched isotopes. Challenges with infrastructure and operational execution may pose short-term obstacles, but the recent hint of increased revenue suggests that the company is taking proactive steps to address these issues under new leadership.

Bear case

ASP Isotopes is a relatively new company, with promising technologies for isotope enrichment that could give it a competitive advantage in the medical, semiconductor, and nuclear industries. However, the company is still in the development stage and faces risks related to scaling production, securing regulatory approvals and permits, and managing its financing and debt. Additionally, there are concerns about political risks in South Africa, where the company does a significant amount of its operations. Proving the scalability and effectiveness of their technologies, as well as securing long-term contracts, will be key for the company's success in the future.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.